SEC Form 4 · accession 0001562180-16-002095
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John R Moore
Officer — VP, General Counsel
Period of report
Apr 1, 2016
Accepted (ET)
Apr 5, 2016 · 6:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 1, 2016 | F | 2,505 | $3.00 | D | 39,754 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Apr 1, 2016 | A | 26,875 | A | — | Apr 1, 2020 | Common Stock | 26,875 | 26,875 | D |
| Stock Option (Right to Buy)F4 | $3.00 | Apr 1, 2016 | A | 161,250 | A | — | Apr 1, 2026 | Common Stock | 161,250 | 161,250 | D |
Explanation of responses
- F1Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F2Includes 20,157 outstanding Restricted Stock Units ("RSUs") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
- F3Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on April 1, 2017.
- F4The option vests in four equal annual installments beginning on April 1, 2017.